| Zea Larochelle, MD | |
|
250 Pleasant St, Concord, NH 03301-7539 | |
| (603) 227-7000 | |
| (603) 230-7218 |
| Full Name | Zea Larochelle |
|---|---|
| Gender | Female |
| Speciality | Emergency Medicine |
| Experience | 12 Years |
| Location | 250 Pleasant St, Concord, New Hampshire |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1013271998 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207P00000X | Emergency Medicine | MT201519 (Pennsylvania) | Secondary |
| 207P00000X | Emergency Medicine | 17067 (New Hampshire) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Concord Hospital | Concord, NH | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Concord Hospital Inc | 6103721790 | 462 |
| Concord Hospital-laconia | 7012326259 | 202 |
News Archive
New findings from a phase 1 trial presented yesterday at the 53rd Annual American Society of Hematology (ASH) Annual Meeting demonstrate Micromet's blinatumomab induces durable responses in patients with extensively pre-treated diffuse large B cell lymphoma.
Cytori Therapeutics announced today the publication of previously reported six-month outcomes from APOLLO, the Company's European clinical trial evaluating adipose-derived stem and regenerative cells (ADRCs) in patients with acute myocardial infarction, as Research Correspondence in the Journal of the American College of Cardiology.
Most biology textbooks explain that the fetal immune system is largely undeveloped and that it learns after being exposed to the world at birth. New research from the University of Pittsburgh School of Medicine and UPMC Children's Hospital of Pittsburgh challenges that paradigm, and provides the first comprehensive look at the immune system of the developing gut.
Syndax Pharmaceuticals, a clinical-stage epigenetics oncology company, announced the National Cancer Institute (NCI) will sponsor a multi-center phase 2 study of Syndax's lead product entinostat, a novel inhibitor of histone deacetylases (HDAC), and anastrozole, an aromatase inhibitor, in postmenopausal women with operable triple negative breast cancer to evaluate biomarkers and surrogates for response.
Researchers at Okayama University have successfully cleaved influenza viral RNA to prevent its replication using novel artificial RNA restriction enzymes in laboratory cell cultures.
› Verified 2 days ago
| Entity Name | Concord Hospital Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1194778571 PECOS PAC ID: 6103721790 Enrollment ID: O20040405000916 |
News Archive
New findings from a phase 1 trial presented yesterday at the 53rd Annual American Society of Hematology (ASH) Annual Meeting demonstrate Micromet's blinatumomab induces durable responses in patients with extensively pre-treated diffuse large B cell lymphoma.
Cytori Therapeutics announced today the publication of previously reported six-month outcomes from APOLLO, the Company's European clinical trial evaluating adipose-derived stem and regenerative cells (ADRCs) in patients with acute myocardial infarction, as Research Correspondence in the Journal of the American College of Cardiology.
Most biology textbooks explain that the fetal immune system is largely undeveloped and that it learns after being exposed to the world at birth. New research from the University of Pittsburgh School of Medicine and UPMC Children's Hospital of Pittsburgh challenges that paradigm, and provides the first comprehensive look at the immune system of the developing gut.
Syndax Pharmaceuticals, a clinical-stage epigenetics oncology company, announced the National Cancer Institute (NCI) will sponsor a multi-center phase 2 study of Syndax's lead product entinostat, a novel inhibitor of histone deacetylases (HDAC), and anastrozole, an aromatase inhibitor, in postmenopausal women with operable triple negative breast cancer to evaluate biomarkers and surrogates for response.
Researchers at Okayama University have successfully cleaved influenza viral RNA to prevent its replication using novel artificial RNA restriction enzymes in laboratory cell cultures.
› Verified 2 days ago
| Entity Name | Concord Hospital-laconia |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1053993741 PECOS PAC ID: 7012326259 Enrollment ID: O20210429001355 |
News Archive
New findings from a phase 1 trial presented yesterday at the 53rd Annual American Society of Hematology (ASH) Annual Meeting demonstrate Micromet's blinatumomab induces durable responses in patients with extensively pre-treated diffuse large B cell lymphoma.
Cytori Therapeutics announced today the publication of previously reported six-month outcomes from APOLLO, the Company's European clinical trial evaluating adipose-derived stem and regenerative cells (ADRCs) in patients with acute myocardial infarction, as Research Correspondence in the Journal of the American College of Cardiology.
Most biology textbooks explain that the fetal immune system is largely undeveloped and that it learns after being exposed to the world at birth. New research from the University of Pittsburgh School of Medicine and UPMC Children's Hospital of Pittsburgh challenges that paradigm, and provides the first comprehensive look at the immune system of the developing gut.
Syndax Pharmaceuticals, a clinical-stage epigenetics oncology company, announced the National Cancer Institute (NCI) will sponsor a multi-center phase 2 study of Syndax's lead product entinostat, a novel inhibitor of histone deacetylases (HDAC), and anastrozole, an aromatase inhibitor, in postmenopausal women with operable triple negative breast cancer to evaluate biomarkers and surrogates for response.
Researchers at Okayama University have successfully cleaved influenza viral RNA to prevent its replication using novel artificial RNA restriction enzymes in laboratory cell cultures.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Zea Larochelle, MD 250 Pleasant St, Concord, NH 03301-7539 Ph: (603) 227-7000 | Zea Larochelle, MD 250 Pleasant St, Concord, NH 03301-7539 Ph: (603) 227-7000 |
News Archive
New findings from a phase 1 trial presented yesterday at the 53rd Annual American Society of Hematology (ASH) Annual Meeting demonstrate Micromet's blinatumomab induces durable responses in patients with extensively pre-treated diffuse large B cell lymphoma.
Cytori Therapeutics announced today the publication of previously reported six-month outcomes from APOLLO, the Company's European clinical trial evaluating adipose-derived stem and regenerative cells (ADRCs) in patients with acute myocardial infarction, as Research Correspondence in the Journal of the American College of Cardiology.
Most biology textbooks explain that the fetal immune system is largely undeveloped and that it learns after being exposed to the world at birth. New research from the University of Pittsburgh School of Medicine and UPMC Children's Hospital of Pittsburgh challenges that paradigm, and provides the first comprehensive look at the immune system of the developing gut.
Syndax Pharmaceuticals, a clinical-stage epigenetics oncology company, announced the National Cancer Institute (NCI) will sponsor a multi-center phase 2 study of Syndax's lead product entinostat, a novel inhibitor of histone deacetylases (HDAC), and anastrozole, an aromatase inhibitor, in postmenopausal women with operable triple negative breast cancer to evaluate biomarkers and surrogates for response.
Researchers at Okayama University have successfully cleaved influenza viral RNA to prevent its replication using novel artificial RNA restriction enzymes in laboratory cell cultures.
› Verified 2 days ago
Miss Kelsey Rainie, ATC, LAT Emergency Medicine Medicare: Not Enrolled in Medicare Practice Location: 10 Avon St, Concord, NH 03301 Phone: 603-848-1859 | |
Ryan J. Sault, DO Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 250 Pleasant St, Concord, NH 03301 Phone: 603-225-2711 Fax: 603-224-6527 | |
Dr. Christina Gale Loporcaro, MD Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 250 Pleasant St, Concord, NH 03301 Phone: 603-225-2711 Fax: 603-224-6527 | |
Dr. Jeremy Semeiks, M.D. PH.D. Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 250 Pleasant St, Concord, NH 03301 Phone: 603-225-2711 Fax: 603-224-6527 | |
Shayna J. Carp, MD Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 250 Pleasant St, Concord, NH 03301 Phone: 603-225-2711 Fax: 603-224-6527 | |
Dr. Fred P. Dutton, MD Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 250 Pleasant Street, Emergency Department, Concord, NH 03301 Phone: 603-225-2711 Fax: 603-224-6527 |